Abstracts tagged "Heart disease"

Abstract Number: 0194 • ACR Convergence 2024
Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus
Ariana Gonzalez-Melendez¹, Jeann Hernandez-Franco², Dylan Cedres-Rivera³ and Abiel Roche-Lima³, ¹University of Puerto Rico - Medical Science Campus, Guaynabo, PR, ²University of Puerto Rico, San Juan, PR, Puerto Rico, ³Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, San Juan, PR, Puerto Rico
Background/Purpose: The most common cause of death among patients with systemic lupus erythematosus (SLE) is cardiovascular disease (CVD). Previous studies have performed cardiovascular risk stratification;…
Abstract Number: 1621 • ACR Convergence 2024
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Ufuoma Mamoh¹, Soziema Salia¹, Joan Morny², Jesse Odion³, Elem Ewuru⁴, Precious Onobraigho⁵, Eugene Omoike⁵, Oyidia Ijioma⁶, Osaruese Ezomo⁷ and Ehizogie Edigin⁸, ¹Medstar Union Memorial Hospital, Baltimore, MD, ²Piedmont Athens Regional Medical Center, Athens, GA, ³Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, ⁴Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, ⁵College of Medicine, University of Benin, Benin, Nigeria, ⁶Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, ⁷Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, ⁸The University of Texas Health Science Center, houston, TX
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed…
Abstract Number: 0296 • ACR Convergence 2024
Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Laura Mas Sánchez¹, JOSE ELOY OLLER RODRIGUEZ², Elena Grau García³, Carmen Riesco Barcena⁴, SAMUEL LEAL⁵, Marta de la Rubia navarro⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Alba Torrat noves⁹, Daniel Ramos Castro¹⁰, Iago Alcantara Alvarez¹¹, Belén Villanueva Mañés¹¹, Miguel Simeo Vinaixa¹², Andrés Pérez Hurtado¹³ and Jose A Román-Ivorra¹⁴, ¹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ²HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁵Hospital La Fe, Valencia, Spain, ⁶Rheumatology department, Hospital La Fe, Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, Valencia, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politecnic La Fe, Valencia, Spain, ¹³Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁴Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: There is limited information about musculoskeletal involvement in Marfan syndrome (MS), especially concerning bone metabolism.Methods: We conducted a retrospective and descriptive study of patients…
Abstract Number: 1957 • ACR Convergence 2024
Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Aïcha Kante¹, Andreea Afana², Damien Sène³, Valérie Bousson⁴, Trecy Goncalves⁵, Edouard Ballout⁵, Solenn Toupin⁵, Jean-Guillaume Dillinger⁶, William Bigot³, Valentin Pagis⁷, Karine Champion³, Ruxandra burlacu⁷, stephane mouly³, Patrick Henry⁶, Theo Pezel⁶ and Cloé Comarmond³, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, ³Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁴Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁵Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, ⁶Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…
Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Aleydis Gonzalez Melendez¹, Rebeca L. Polina-Lugo¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Osvaldo Uresti³, Ricardo I. de la Rosa-Vazquez³, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
Abstract Number: 1958 • ACR Convergence 2024
Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients
Aïcha Kante¹, Andreea Afana², Damien Sène³, Karine Champion³, Valentin Pagis⁴, William Bigot³, Véronique Delcey⁵, Amanda Lopes³, Abdellatif Tazi⁶, Blanca Amador Borrero⁴, Bruno Crestani⁷, Claire Baladi⁸, Valérie Bousson⁹, Trecy Goncalves¹⁰, Edouard Ballout¹⁰, Solenn Toupin¹⁰, stephane mouly³, Jean-Guillaume Dillinger¹¹, Patrick Henry¹¹, Theo Pezel¹¹ and Cloé Comarmond³, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, ³Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁴Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, ⁵Department of Infectious diseases, Lariboisère University Hospital, Paris, Ile-de-France, France, ⁶National Reference Center for Histiocytoses, Department of Pulmonology, AP-HP, Saint-Louis Hospital, Paris, France, ⁷National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, ⁸Université d’Angers, Department of Cardiology, University Hospital of Angers, Angers, France, ⁹Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ¹⁰Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, ¹¹Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France
Background/Purpose: Cardiac sarcoidosis (CS) is an underdiagnosed condition characterized by the formation of non-caseating granuloma in the myocardium, potentially leading to arrhythmia, acute heart failure,…
Abstract Number: 0347 • ACR Convergence 2024
Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
Elizabeth Matz¹ and Ram Singh², ¹UCLA David Geffen School of Medicine, Los Angeles, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…
Abstract Number: 2009 • ACR Convergence 2024
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Amara Sarwal¹, Augustine Takyi¹, Guo Wei¹, McKenna Nevers¹, Ravinder Singh¹, Sydney Hartsell¹, Robert Boucher¹, Niharika Katkam¹, Akhil Chakravartula¹, Jincheng Shen¹, Srinivasan Beddhu¹ and Naomi Schlesinger², ¹University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Bas Dijkshoorn¹, Sreen Mohamed², Romy Hansildaar², Henk Everaars³, Geoffrey Mooij³, Luuk Hopman³, Paul Knaapen³, Lourens Robbers³ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
Abstract Number: 2026 • ACR Convergence 2024
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Rebeca L. Polina-Lugo¹, Aleydis Gonzalez Melendez¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Annette Dominguez-Guerra³, Victoria P. Limas-Martínez¹, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
Abstract Number: 0556 • ACR Convergence 2024
Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis
Asier García-Alija¹, Hye Sang Park¹, Patricia Moya¹, Ana Laiz¹, Carla Marco², Albert Casals¹, Concepcion Pitarch², Cesar Diaz-Torné¹, Berta Paula Magallares³, Ivan Castellvi Barranco¹, Susana Fernández-Sánchez¹, Andrea García-Guillen², Jose Luis Tandaipan¹, Helena Codes-Mendez¹, Guillem Verdaguer¹, Luis Sainz¹ and Hèctor Corominas¹, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²Hospital Dos de Maig, Barcelona, Spain, ³Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain
Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…
Abstract Number: 2046 • ACR Convergence 2024
Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
Antonio Brucato¹, Elisa Ceriani², Francesco Agozzino³, Silvia Berra⁴, Antonio Gidaro², Silvia Macchi⁵, Letizia Vena⁵, Paolo Bindi⁵, Alberto Pavarani⁶, Francesco Moda⁷, Ludovico Luca Sicignano⁸, Celeste Murace⁸, Elena Verrecchia⁸, Caterina Chiara Decarlini⁹, Silvia Maestroni¹⁰, Gabriella Marinaro⁴, Lucia Trotta³, Massimo Pancrazi³, Lisa Serati³, Enrica Negro³, Claudia Gabiati³, Elisa Calabrò³, Angela Mauro¹¹, Luisa Carrozzo³, Emanuele Bizzi³ and Massimo Imazio¹², ¹Department of Biomedical and Clinical Sciences, University of Milano, Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Lombardia, Italy, ²Department of Internal Medicine, Ospedale Luigi Sacco, Milano, Milan, Italy, ³Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milan, Italy, ⁴Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Italy, ⁵University of Milano, Milan, Italy, ⁶University of Milano, Milan, ⁷Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁸Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Rome, Italy, ⁹Cardiology Division, Cardiovascular Department, San L. Mandic Hospital, Merate, Lecco, Italy, ¹⁰Internal Medicine Department, Papa Giovanni XXIII Hospital, Bergamo, Bergamo, Italy, ¹¹Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy, ¹²University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Milan, Italy
Background/Purpose: Recurrent pericarditis (RP) challenges pts and clinicians in terms of long-term management. Objective of this study was to evaluate the remission rate (drug-free for…
Abstract Number: 1469 • ACR Convergence 2023
Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Daniel Joyce¹, Jeffrey. Berger², Allison Guttmann³, Ghadeer Hasan⁴, Jill Buyon⁵, H Michael Belmont¹, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles Helmick¹⁴, Kamil Barbour¹⁵, Heather Gold¹⁶, Hilary Parton¹⁷ and Peter Izmirly², ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Atlantic Health System, Summit, NJ, ⁴Optum, Jersey City, NJ, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹SUNY Downstate Health Sciences University, Brooklyn, NY, ¹²Albert Einstein College of Medicine, Bronx, NY, ¹³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁴NA, Atlanta, GA, ¹⁵Centers for Disease Control and Prevention, Atlanta, GA, ¹⁶New York University, New York, NY, ¹⁷New York City Department of Health and Mental Hygiene, Queens, NY
Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…
Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Ye Liu¹, Tarun Arora², S. Bobo Tanner³ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].